Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide

Circulation: Heart Failure

Volumn 4, Issue 2, 2011, Pages 114-120

  Ibebuogu, Uzoma N ^a   Gladysheva, Inna P ^a,b   Houng, Aiilyan K ^a,b   Reed, Guy L ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Atrial natriuretic peptide; Biomarker; Heart failure

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CORIN PROTEIN, HUMAN; CYCLIC GMP; SERINE PROTEINASE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMAN; IMMUNOASSAY; MALE; PLASMA; PRIORITY JOURNAL; ADOLESCENT; BLOOD; CASE CONTROL STUDY; DOWN REGULATION; HEART STROKE VOLUME; HEART VENTRICLE FUNCTION; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYCLIC GMP; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; SERINE ENDOPEPTIDASES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; VENTRICULAR FUNCTION; YOUNG ADULT;

EID: 79955939945     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.895581     Document Type: Article

References (61)

1. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358: 2148-2159.
2. Collins SP, Ronan-Bentle S, Storrow AB. Diagnostic and prognostic usefulness of natriuretic peptides in emergency department patients with dyspnea. Ann Emerg Med. 2003;41:532-545. (Pubitemid 36373522)
3. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948-1955.
4. Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol. 1981;47:33-39. (Pubitemid 11217567)
5. Chati Z, Mertes PM, Aliot E, Zannad F. Plasma levels of atrial natriuretic peptide and of other vasoconstricting hormones in patients with chronic heart failure: Relationship to exercise capacity. Int J Cardiol. 1996;57: 135-142. (Pubitemid 26423569)
6. Gladysheva IP, Robinson BR, Houng AK, Kovats T, King SM. Corin is co-expressed with pro-ANP and localized on the cardiomyocyte surface in both zymogen and catalytically active forms. J Mol Cell Cardiol. 2008;44:131-142.
7. Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A. 2000;97:8525-8529. (Pubitemid 30639706)
8. Hooper JD, Scarman AL, Clarke BE, Normyle JF, Antalis TM. Localization of the mosaic transmembrane serine protease corin to heart myocytes. Eur J Biochem. 2000;267:6931-6937.
9. Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: Its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost. 1999;81:1-7. (Pubitemid 29041639)
10. Tran KL, Lu X, Lei M, Feng Q, Wu Q. Upregulation of corin gene expression in hypertrophic cardiomyocytes and failing myocardium. Am J Physiol Heart Circ Physiol. 2004;287:H1625-H1631. (Pubitemid 39313267)
11. Langenickel TH, Pagel I, Buttgereit J, Tenner K, Lindner M, Dietz R, Willenbrock R, Bader M. Rat corin gene: Molecular cloning and reduced expression in experimental heart failure. Am J Physiol Heart Circ Physiol. 2004;287:H1516-H1521. (Pubitemid 39313254)
12. de Bold AJ. Atrial natriuretic factor: A hormone produced by the heart. Science. 1985;230:767-770. (Pubitemid 16193965)
13. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145-1147. (Pubitemid 16016312)
14. Yamamoto K, Burnett JC Jr, Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol. 1997;273:H2406-H2414.
15. Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. Lancet. 1997;349:1307-1310. (Pubitemid 27192482)
16. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-328. (Pubitemid 28366422)
17. Wu F, Yan W, Pan J, Morser J, Wu Q. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem. 2002;277: 16900-16905. (Pubitemid 34967716)
18. Schwartz D, Geller DM, Manning PT, Siegel NR, Fok KF, Smith CE, Needleman P. Ser-Leu-Arg-Arg-atriopeptin III: The major circulating form of atrial peptide. Science. 1985;229:397-400. (Pubitemid 15073086)
19. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27:47-72. (Pubitemid 43228238)
20. Chang MS, Lowe DG, Lewis M, Hellmiss R, Chen E, Goeddel DV. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases. Nature. 1989;341:68-72. (Pubitemid 19220660)
21. Burnett JC Jr, Granger JP, Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol. 1984;247:F863-F866. (Pubitemid 15178898)
22. Chen HH, Burnett JC Jr. The natriuretic peptides in heart failure: Diagnostic and therapeutic potentials. Proc Assoc Am Physicians. 1999;111: 406-416. (Pubitemid 29446883)
23. Saito Y, Nakao K, Nishimura K, Sugawara A, Okumura K, Obata K, Sonoda R, Ban T, Yasue H, Imura H. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: Beneficial effects on left ventricular function. Circulation. 1987;76:115-124. (Pubitemid 17093199)
24. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12:131-142. (Pubitemid 46916959)
25. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989;13:1534-1539. (Pubitemid 19145552)
26. Wallen T, Landahl S, Hedner T, Hall C, Saito Y, Nakao K. Atrial natriuretic peptides predict mortality in the elderly. J Intern Med. 1997; 241:269-275. (Pubitemid 27223992)
27. Omland T, Bonarjee VV, Nilsen DW, Sundsfjord JA, Lie RT, Thibault G, Dickstein K. Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: Comparison with atrial natriuretic factor (99 -126) and clinical evaluation. Br Heart J. 1993;70: 409-414. (Pubitemid 23342799)
28. Hall C, Rouleau JL, Moye L, de Champlain J, Bichet D, Klein M, Sussex B, Packer M, Rouleau J, Arnold MO. N-terminal proatrial natriuretic factor: An independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994;89:1934-1942.
29. Gibson TR, Shields PP, Glembotski CC. The conversion of atrial natriuretic peptide (ANP)-(1-126) to ANP-(99-126) by rat serum: Contribution to ANP cleavage in isolated perfused rat hearts. Endocrinology. 1987;120:764-772. (Pubitemid 17020435)
30. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol. 2002;40:976-982. (Pubitemid 34994995)
31. Gladysheva IP, King SM, Houng AK. N-glycosylation modulates the cell-surface expression and catalytic activity of corin. Biochem Biophys Res Commun. 2008;373:130-135.
32. Zolotarjova N, Martosella J, Nicol G, Bailey J, Boyes BE, Barrett WC. Differences among techniques for high-abundant protein depletion. Proteomics. 2005;5:3304-3313. (Pubitemid 41192037)
33. Lee ME, Miller WL, Edwards BS, Burnett JC Jr. Role of endogenous atrial natriuretic factor in acute congestive heart failure. J Clin Invest. 1989;84:1962-1966. (Pubitemid 20016204)
34. Anderson JV, Woodruff PW, Bloom SR. The effect of treatment of congestive heart failure on plasma atrial natriuretic peptide concentration: A longitudinal study. Br Heart J. 1988;59:207-211. (Pubitemid 18045123)
35. Berglund H, Bevegard S, Carlens P, Hedner J, Hedner T. Atrial natriuretic peptide during acute treatment of congestive heart failure. Clin Physiol (Oxford, England). 1988;8:155-162.
36. Marumo F, Kurosawa T, Takeda S, Katoh Y, Hasegawa N, Ando K. Changes of molecular forms of atrial natriuretic peptide after treatment for congestive heart failure. Klinische Wochenschrift. 1988;66:675-681.
37. Takahashi M, Takeda S, Kurokawa S, Kubo T, Fukuda N, Izumi T. Cyclic GMP production by ANP, BNP, and NO during worsening and improvement of chronic heart failure. Jpn Heart J. 2003;44:713-724. (Pubitemid 41518972)
38. Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, Yokoyama H, Tanaka K, Mizuno K, Nejima J, Kinoshita M. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: The PROTECT multicenter randomized controlled study. Circ J. 2008;72:1787-1793.
39. Andreassi MG, Del Ry S, Palmieri C, Clerico A, Biagini A, Giannessi D. Up-regulation of 'clearance' receptors in patients with chronic heart failure: A possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur J Heart Fail. 2001;3:407-414. (Pubitemid 32780524)
40. Charloux A, Piquard F, Doutreleau S, Brandenberger G, Geny B. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest. 2003;33:769-778. (Pubitemid 37082863)
41. Rame JE, Tam SW, McNamara D, Worcel M, Sabolinski ML, Wu AH, Dries DL. Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: Results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail. 2009;2:541-548.
42. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, Shaknovich A, Pondolfino K, Clark M, Camargo MJF, Scarborough RM, Lewicki JA. Atrial natriuretic factor in normal subjects and heart failure patients: Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78:1362-1374. (Pubitemid 17181577)
43. Crozier IG, Nicholls MG, Ikram H, Espiner EA, Gomez HJ, Warner NJ. Haemodynamic effects of atrial peptide infusion in heart failure. Lancet. 1986;2:1242-1245. (Pubitemid 17182838)
44. Tomita Y, Kim DH, Magoori K, Fujino T, Yamamoto TT. A novel low-density lipoprotein receptor-related protein with type II membrane protein-like structure is abundant in heart. J Biochem (Tokyo). 1998;124: 784-789. (Pubitemid 28488158)
45. Chan JC, Knudson O, Wu F, Morser J, Dole WP, Wu Q. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A. 2005;102:785-790. (Pubitemid 40282743)
46. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87:1402-1412.
47. Aburaya M, Suzuki E, Minamino N, Kangawa K, Tanaka K, Matsuo H. Concentration and molecular forms of brain natriuretic peptide in rat plasma and spinal cord. Biochem Biophys Res Commun. 1991;177: 40-47.
48. Ogawa Y, Nakao K, Mukoyama M, Shirakami G, Itoh H, Hosoda K, Saito Y, Arai H, Suga S, Jougasaki M, Itoh H, Hosoda K, Yamada T, Kambayashi Y, Inouye K, Imura H. Rat brain natriuretic peptide-tissue distribution and molecular form. Endocrinology. 1990;126:2225-2227. (Pubitemid 20139777)
49. Kambayashi Y, Nakao K, Itoh H, Hosoda K, Saito Y, Yamada T, Mukoyama M, Arai H, Shirakami G, Suga S, Ogawa Y, Jougasaki M, Minamino N, Kangawa K, Matsuo H, Inouye K, Imura H. Isolation and sequence determination of rat cardiac natriuretic peptide. Biochem Biophys Res Commun. 1989;163:233-240. (Pubitemid 19227296)
50. Rame JE, Drazner MH, Post W, Peshock R, Lima J, Cooper RS, Dries DL. Corin I555(P568) allele is associated with enhanced cardiac hypertrophic response to increased systemic afterload. Hypertension. 2007;49: 857-864. (Pubitemid 351664223)
51. Dries DL, Victor RG, Rame JE, Cooper RS, Wu X, Zhu X, Leonard D, Ho SI, Wu Q, Post W, Drazner MH. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation. 2005;112:2403-2410. (Pubitemid 41504489)
52. Wang W, Liao X, Fukuda K, Knappe S, Wu F, Dries DL, Qin J, Wu Q. Corin variant associated with hypertension and cardiac hypertrophy exhibits impaired zymogen activation and natriuretic peptide processing activity. Circ Res. 2008;103:502-508.
53. Woollard KJ, Suhartoyo A, Harris EE, Eisenhardt SU, Jackson SP, Peter K, Dart AM, Hickey MJ, Chin-Dusting JP. Pathophysiological levels of soluble P-selectin mediate adhesion of leukocytes to the endothelium through Mac-1 activation. Circ Res. 2008;103:1128-1138.
54. Deschamps AM, Spinale FG. Matrix modulation and heart failure: New concepts question old beliefs. Curr Opin Cardiol. 2005;20:211-216. (Pubitemid 40704878)
55. Yan AT, Yan RT, Spinale FG, Afzal R, Gunasinghe HR, Arnold M, Demers C, McKelvie RS, Liu PP. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail. 2006;12:514-519. (Pubitemid 44316923)
56. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089-2096.
57. Kramer F, Sandner P, Klein M, Krahn T. Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat. Biomarkers. 2008;13:270-281. (Pubitemid 351552473)
58. Vorovich EE, Chuai S, Li M, Averna J, Marwin V, Wolfe D, Reilly MP, Cappola TP. Comparison of matrix metalloproteinase 9 and brain natriuretic peptide as clinical biomarkers in chronic heart failure. Am Heart J. 2008;155:992-997.
59. Gonzalez A, Lopez B, Ravassa S, Beaumont J, Arias T, Hermida N, Zudaire A, Diez J. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc Res. 2009;81:509-518.
60. Knappe S, Wu F, Masikat MR, Morser J, Wu Q. Functional analysis of the transmembrane domain and activation cleavage of human corin: Design and characterization of a soluble corin. J Biol Chem. 2003;278: 52363-52370. (Pubitemid 38035826)
61. Ibebuogu UN, Gladysheva IP, Reed GL. Is heart failure due to impaired cleavage and activation of atrial natriuretic peptide? J Am Coll Cardiol. 2009;53:A468-A469.